Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATEEN: Sacituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer
NCT06100874Phase 2Active, not recruiting
- Sponsor
- Adrienne G. Waks
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in breast cancer, sponsored by Adrienne G. Waks. Started Nov 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06100874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100874.